title: Tocilizumab for refractory organising pneumonia associated with Sjögren's disease.
abstract: Lung involvement in primary Sjögren syndrome occurs in approximately 10-20% of patients. Tocilizumab, an anti-interleukin-6 receptor antibody, has demonstrated efficacy and safety in small series of systemic sclerosis, and systemic lupus erythematosus, but its effect on interstitial lung manifestations of connective tissue diseases is not well known. We report the use of tocilizumab in a refractory organising pneumonia associated with Sjögren's disease. Our observation suggests that tocilizumab could be an alternative therapeutic in refractory organising pneumonia.
authors.affiliation: Department of Service de Pneumologie A, Hôpital Bichat-Claude Bernard, Paris, France Université Denis Diderot, Paris 7, Unité INSERM U1152, Paris, France.
authors.forename: Aurelien
authors.initials: A
authors.lastname: Justet
authors.affiliation: Department of Service de Rhumatologie, Hôpital Bichat Claude Bernard, Paris, France.
authors.forename: Sebastien
authors.initials: S
authors.lastname: Ottaviani
authors.affiliation: Department of Service de Rhumatologie, Hôpital Bichat Claude Bernard, Paris, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Dieudé
authors.affiliation: Department of Service de Pneumologie A, Hôpital Bichat-Claude Bernard, Paris, France Université Denis Diderot, Paris 7, Unité INSERM U1152, Paris, France.
authors.forename: Camille
authors.initials: C
authors.lastname: Taillé
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D018549:Cryptogenic Organizing Pneumonia / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011239:Prednisolone / Q000627:therapeutic use; D011859:Radiography; D019947:Receptors, Interleukin-6; D000069283:Rituximab / Q000627:therapeutic use; D012859:Sjogren's Syndrome / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007155:Immunologic Factors; D019947:Receptors, Interleukin-6; D000069283:Rituximab; D011239:Prednisolone; C502936:tocilizumab